Arrowhead Pharmaceuticals Advances Plozasiran Therapy for Familial Chylomicronemia Syndrome FDA Approval

Arrowhead Pharmaceuticals Advances Plozasiran for Familial Chylomicronemia Syndrome

Arrowhead Pharmaceuticals, Inc. announces a significant milestone with the U.S. Food and Drug Administration's (FDA) acceptance of its New Drug Application (NDA) for plozasiran, an innovative therapy targeting familial chylomicronemia syndrome (FCS). This severe genetic disorder is characterized by extremely high triglyceride levels in the blood, leading to serious complications, including acute pancreatitis. The FDA has set a Prescription Drug User Fee Act (PDUFA) action date of November 18, 2025, signifying a pivotal step towards making this treatment accessible to patients suffering from this debilitating condition. The FDA's indication that it does not plan to convene an advisory committee meeting suggests confidence in the data presented by Arrowhead, paving the way for a smoother regulatory path.

The NDA is supported by robust clinical data from the PALISADE Phase 3 study, which has shown remarkable efficacy for plozasiran. This study met its primary endpoint and all key secondary endpoints, demonstrating significant reductions in triglyceride levels, apolipoprotein C-III, and the incidence of acute pancreatitis. Notably, participants receiving the 25 mg dose of plozasiran achieved a median triglyceride reduction of 80%, alongside an 83% decrease in the risk of acute pancreatitis compared to the placebo group. These compelling results underline the potential of plozasiran not only to improve clinical outcomes for patients with FCS but also to alleviate the broader issues related to elevated triglyceride levels.

Dr. Chris Anzalone, President and CEO of Arrowhead Pharmaceuticals, expresses appreciation for the dedicated efforts of the team involved in the PALISADE study. He emphasizes the importance of these positive results for patients and the company's commitment to ensuring a successful commercial launch of plozasiran, pending FDA approval. Arrowhead plans to expand its regulatory submissions for plozasiran to additional authorities in 2025, reflecting its strategic goal of broadening access to this promising therapy for patients worldwide.

In addition to its FDA application, Arrowhead Pharmaceuticals showcases its dedication to transparency and scientific communication by presenting the efficacy and safety results from the PALISADE study at prominent medical conferences. The findings are also published in reputable journals, including Circulation and The New England Journal of Medicine, ensuring that the scientific community and healthcare professionals are informed about the advancements in treating FCS.

As Arrowhead Pharmaceuticals moves forward, the company's focus remains on patient outcomes and the potential of plozasiran to transform the treatment landscape for familial chylomicronemia syndrome, marking a critical development in the biopharmaceutical industry.